Navigation Links
AssureRx Health Launches Personalized Medicine Test for ADHD
Date:5/7/2012

MASON, Ohio, May 7, 2012 /PRNewswire/ -- AssureRx Health, Inc. today announced it has launched a personalized medicine test for the growing number of children and adults diagnosed with attention deficit hyperactivity disorder (ADHD). The new pharmacogenomic test can assist clinicians with important medication decisions that result from genomic differences in how individual patients tolerate ADHD medications.

GeneSightRx ADHD analyzes variations in three genes that influence how a patient might metabolize certain medications used to treat ADHD in children and adults.  Understanding a patient's unique genomic profile may help a clinician individualize a patient's medication selection and avoid side effects that often occur with these medications. The test provides objective, evidence-based information for clinicians to personalize medication selection for each patient.

The GeneSightRx ADHD analysis is based on pharmacogenomics, FDA-approved manufacturer's drug labels, published peer reviewed research, and proven pharmacology. The new ADHD test adds to the company's treatment decision support products that include GeneSightRx Psychotropic, a psychiatric pharmacogenomic product that tests important genomic variants affecting metabolism to psychiatric medications for individual patients. 

ADHD diagnoses increased 66 percent from 6.2 million in 2000 to 10.4 million in 2010, according to a study published in the March/April 2012 issue of Academic Pediatrics. ADHD is the most common childhood disorder and can continue into adulthood. Symptoms of ADHD include an inability to stay focused or pay attention, difficulty controlling behavior, and hyperactivity.

"ADHD is a neurobehavioral disorder affecting millions of children and adults. With the introduction of GeneSightRx ADHD, clinicians now have an objective, evidence-based tool for individualizing ADHD medications," said James S. Burns, president and CEO of AssureRx Health. "Our goal is to build a portfolio of innovative pharmacogenomic and other treatment decision support products to help physicians individualize the treatment of patients with neuropsychiatric and other disorders."

When a clinician orders the test, a DNA sample is taken from the patient with a simple, non-invasive cheek swab.  The specimen is sent overnight to AssureRx Health's CLIA-certified and CAP-accredited laboratory. The ordering clinician receives the patient report via a secure online portal that presents the patient's genomic information in an easy-to-read and clinically actionable format.

About GeneSightRx

GeneSightRx is a laboratory developed genomic test that uses cutting edge technology to measure and analyze clinically important genomic variants in the treatment of psychiatric disorders. The results of the GeneSightRx report can help a clinician understand the way a patient's unique genomic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenomics, the study of genomic factors that influence an individual's response to drug treatments, FDA approved manufacturer's drug labels, peer-reviewed scientific and clinical publications, and proven drug pharmacology. Quick turnaround time, combined with a customized report of the patient's genomic makeup, clinical experience, and other factors can help a physician make personalized drug treatment choices for each individual patient. To learn more about pharmacogenomics and GeneSightRx, please click here. Be sure to watch the educational video on our YouTube channel.

About AssureRx Health

AssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenomics dedicated to helping clinicians determine the right drug for individual patients suffering from neuropsychiatric and other disorders. The GeneSightRx analysis is based on pharmacogenomics the study of the genomic factors that influence an individual's response to drug treatments, using FDA approved manufacturers' drug labels, scientific and clinical peer-reviewed publications, and proven pharmacology. The company was founded to commercialize industry-leading personalized medicine technology. To learn more about pharmacogenomics and GeneSightRx, visit www.assurerxhealth.com.

Contact:
Troy May
Marketing Communications Manager
AssureRx Health Inc.
513-234-0510 Office
TMay@AssureRxHealth.com

 


'/>"/>
SOURCE AssureRx Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Medco Research Institute® and AssureRx Health Initiate Pilot Program to Evaluate Adoption and Clinical Impact of Pharmacogenetic Testing for Selection of Psychotropic Medications
2. AssureRx Health Raises $11 Million Series B Financing
3. AssureRx Expands GeneSightRx® Pharmacogenetic Profile with Sixth Gene to Enhance Guidance of Psychiatric Drug Prescribing
4. AssureRx Appoints Senior Executives in Key Roles to Drive Company Growth
5. Seventeen Banner Health facilities achieve final stage of electronic medical record adoption
6. Watson to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
7. Aperture Health, Inc. focuses in on IV Therapy Value Creation and the Merger and Acquisition Activities in the Home Infusion Therapy Sector.
8. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
9. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
10. Hill-Rom to Participate in the Bank of America Merrill Lynch 2012 Health Care Conference
11. Optimer Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Medical information groups within ... their self-service capabilities to manage inquiries from external ... New research from consulting leader Best Practices, ... self-service website portals where HCPs can sign on ... of many findings to emerge from the new ...
(Date:2/24/2017)... Februar 2017 ITL Limited, ( ASX: ... ist erfreut, für das zum 31. Dezember 2016 ... exzellente Ergebnisse vorlegen zu können. Eine vollständige Präsentation ... finden Sie hier . ... 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 ... gives comprehensive insights on the various drugs ... The report covers all the drugs that ... Preclinical & Clinical). The pipeline focuses on ... small molecules, antibodies, stem cell therapies, recombinant ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... 24, 2017 , ... Houston dentist , Dr. Behzad ... Dental Center. Currently, patients can get single dental implants for $3,599 and All ... learn more about these offers by contacting Antoine Dental Center. Both of these ...
(Date:2/24/2017)... ... February 24, 2017 , ... Dr. Ronald ... officially announced the appointment of Peter A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, ... (LUCOM), beginning April 10. Dr. Bell comes to Liberty from the Ohio University ...
(Date:2/24/2017)... Texas (PRWEB) , ... February 24, 2017 , ... ... to The Medical Center at Craig Ranch building at 8080 State Highway 121, Suite ... Medical District with easy access to Highway 121. , As the practice has grown, ...
(Date:2/24/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has published a ... an astounding statement when he says that the entire Bible was written for the ... times so plainly that anyone should be able to see the time period. He ...
(Date:2/24/2017)... Lawn, NJ (PRWEB) , ... February 24, 2017 ... ... with robust marketing services, which specializes in thought leadership , media relations, ... marketing campaigns and services that will be powered through Act-On, an intuitive marketing ...
Breaking Medicine News(10 mins):